ArticleJournal of human hypertension2018
Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients.
Article in Journal of human hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Osteoglycin and Bone-a Systematic Review.Current osteoporosis reports · 2019Pooled it
- The relationship between serum Lumican levels and myocardial fibrosis in patients with hypertrophic cardiomyopathy.Biomarkers in medicine · 2025Article
- Lumican Is Both a Novel Risk Factor and Potential Plasma Biomarker for Vascular Aging, Capable of Promoting Vascular Smooth Cells Senescence Through Interacting With Integrin α2β1.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Lumican, a Multifunctional Cell Instructive Biomarker Proteoglycan Has Novel Roles as a Marker of the Hypercoagulative State of Long Covid Disease.International journal of molecular sciences · 2024Review
- Exploring the role of osteoglycin in type 2 diabetes: implications for insulin resistance and vascular pathophysiology.American journal of physiology. Endocrinology and metabolism · 2023Article
- Additional Acupuncture Confers a Favorable Long-Term Prognosis for Elderly Hypertensive Patients with Carotid Atherosclerosis after Atorvastatin Treatment.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research suggested that certain small leucine-rich repeat proteoglycans (SLRPs) were involved in the development of atherosclerosis. The present study investigated the relationship between carotid atherosclerosis plaque and the circulating levels of some SLRPs, including decorin, lumican, and osteoglycin, in essential hypertension. In total, 176 essential hypertensive patients were recruited (mean age 62.1 ± 9.4, male 56.8%) in this study and were classified into two groups: patients with carotid artery plaque (n = 105, 60%) and patients without carotid artery plaque (n = 71, 40%). Patients with carotid artery plaque had higher serum concentration of lumican than patients without carotid plaque (58.0 ± 1.6 vs. 52.3 ± 2.1 ng/ml, p = 0.04) after adjusting for conventional cardiovascular risk factors. There were no differences in decorin and osteoglycin between the two groups. Multivariable logistic regression analysis revealed that lumican levels (Odds ratio (OR) per standard deviation increase, 1.598; 95% confidence interval (CI), 1.012 ~ 2.523; p = 0.04), 24-h mean systolic blood pressure (OR, 1.045; 95% CI, 1.012 ~ 1.079; p = 0.006) and the use of angiotensin receptor blocker (OR, 2.813; 95% CI, 1.023 ~ 7.734; p = 0.045) were independently associated with carotid artery plaque. Besides carotid artery plaque, lumican was related to impaired glucose tolerance (r = 0.162, p = 0.046) and adversely related to osteoglycin (r = - 0.273, p < 0.001), whereas unrelated to age, sex, BMI, diabetes, blood pressure, serum lipids, high-sensitivity C-reactive protein, or carotid intima-media thickness in univariate correlation analyses. Circulating lumican was independently associated with carotid atherosclerosis plaque in essential hypertensive patients, indicating that SLRPs might be used as a promising molecular marker for atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.